Skip to main content
SpringerLink
Log in

Chemotherapie des malignen Pleuramesothelioms

  • Chapter
Pleuramesotheliom

  • 273 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 9.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aisner J, Wiernik PH (1981) Chemotherapy in the treatment of malignant mesothelioma. Semin Oncol 8: 335–343

    CAS  PubMed  Google Scholar 

  • Alberts AS, Falkson G, Van Zyl L (1988) Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 80: 698–700

    CAS  PubMed  Google Scholar 

  • Andersen MK, Krarup-Hansen A, Martensson G et al. (1999) Ifosfamide in malignant mesothelioma: a phase II study. Lung Cancer 24: 39–43

    Article  CAS  PubMed  Google Scholar 

  • Antman KH, Blum RH, Greenberger JS et al. (1980) Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68: 356–362

    Article  CAS  PubMed  Google Scholar 

  • Ardizzoni A, Pennucci MC, Castagneto B et al. (1994) Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 17: 80–82

    CAS  PubMed  Google Scholar 

  • Ardizzoni A, Rosso R, Salvati F et al. (1991) Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67: 2984–2987

    CAS  PubMed  Google Scholar 

  • Astoul P, Picat-Joossen D, Viallat JR et al. (1998) Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 83: 2099–2104

    Article  CAS  PubMed  Google Scholar 

  • Aversa SL, Crcuri C, De Pangher V et al. (1998) Carboplatin and Gemcitabine chemotherapy for malignant pleural mesothelioma (MPM): A phase II study of the GSTPV. Ann Oncol 9: 117

    Google Scholar 

  • Baas P, Ardizzoni A, Debruyne C et al. (2002) Activity of Tomudex in malignant pleural mesothelioma. Proc IMIG — International Mesothelioma Interest Group — 6th Meeting, December 1–4, Perth, Australia (Abstr. 13)

    Google Scholar 

  • Baas P, van Meerbeeck J, Groen H et al. (2000) Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol: 11: 697–700

    Article  CAS  PubMed  Google Scholar 

  • Bajorin D, Kelsen D, Mintzer DM (1987) Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 71: 857–858

    CAS  PubMed  Google Scholar 

  • Bednar ME, Chahinian P (1999) Paclitaxel and carboplatin for malignant mesothelioma. Proc ASCO 18: 496a (Abstr. 1916)

    Google Scholar 

  • Belani CP, Adak S, Aisner S et al. (1999) Docetaxel for Malignant Mesothelioma: Phase II Study of the Eastern Cooperative Oncology Group (ECOG 2595). Proc ASCO 18: 474a (Abstr. 1829)

    Google Scholar 

  • Bischoff HG, Manegold C, Knopp K et al. (1998) Gemcitabine (Gemzar symptoms in malignant pleural mesothelioma. Proc ASCO 17: 464 (Abstr. 1784)

    Google Scholar 

  • Boutin C, Irisson M, Guerin JC et al. (1987) Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat Rep 71: 205–206

    CAS  PubMed  Google Scholar 

  • Boutin C, Nussbaum E, Monnet I et al. (1994) Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 74: 2460–2467

    CAS  PubMed  Google Scholar 

  • Bretti S, Berruti A, Dogliotti L et al. (1998) Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori 84: 558–561

    CAS  PubMed  Google Scholar 

  • Bunn P, Paoletti P, Niyikiza C et al. (2001) Vitamin B12 and folate reduce toxicity of Alimta (Pemetrexed disodium, LY1514, MTA), Proc ASCO 20: 76a (Abstr. 300)

    Google Scholar 

  • Byrne MJ, Davidson JA, Musk AW et al. (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17: 25–30

    CAS  PubMed  Google Scholar 

  • Caliandro R, Boutin C, Perol M et al. (1997) Phase II study of Paclitaxel and cisplatin in advanced pleural malignant mesothelioma. Lung Cancer 18(Suppl 1): 19 (Abstr. 62)

    Google Scholar 

  • Cantwell BM, Earnshaw M, Harris AL (1986) Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep 70: 1335–1336

    CAS  PubMed  Google Scholar 

  • Carmichael J, Cantwell BM, Harris AL (1989) A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 25: 911–912

    CAS  PubMed  Google Scholar 

  • Castagneto B, Zai S, Mutti L et al. (2001) Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer 31: 303–310

    Article  CAS  PubMed  Google Scholar 

  • Chahinian AP, Holland JF, Mandel EM (1978) Chemotherapy for malignant mesothelioma with adriamycin and continuous infusion of 5-azacytidine. Cancer Treat Rep 62: 1108–1109

    CAS  PubMed  Google Scholar 

  • Chahinian AP, Antman K, Goutsou M et al. (1993) Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11: 1559–1565

    CAS  PubMed  Google Scholar 

  • Christmas TI, Manning LS, Garlepp MJ et al. (1993) Effect of interferon-alpha 2a on malignant mesothelioma. J Interferon Res 13: 9–12

    CAS  PubMed  Google Scholar 

  • Colbert N, Vannetzel JM, Izrael V et al. (1985) A prospective study of detorubicin in malignant mesothelioma. Cancer 56: 2170–2174

    CAS  PubMed  Google Scholar 

  • Cowan JD, Green S, Lucas J et al. (1988) Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 6: 247–248

    Article  CAS  PubMed  Google Scholar 

  • Curran D, Sahmoud T, Therasse P et al. (1998) Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16: 145–152

    CAS  PubMed  Google Scholar 

  • Davidson JA, Musk AW, Wood BR et al. (1998) Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J Immunother 21: 389–398

    CAS  PubMed  Google Scholar 

  • Dimitrov NV, Egner J, Balcueva E et al. (1982) High-dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma. Cancer 50: 1245–1247

    CAS  PubMed  Google Scholar 

  • Dirix LY, van Meerbeeck J, Schrijvers D et al. (1994) A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 5: 653–655

    CAS  PubMed  Google Scholar 

  • Eagan RT, Frytak S, Richardson RL et al. (1986) Phase II trial of diaziquone in malignant mesothelioma. Cancer Treat Rep 70: 429

    CAS  PubMed  Google Scholar 

  • Eisenhauer EA, Evans WK, Raghavan D et al. (1986) Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep 70: 1029–1030

    CAS  PubMed  Google Scholar 

  • Eisenhauer EA, Evans WK, Murray N et al. (1988) A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma. An NCI Canada Clinical Trials Group Study. Invest New Drugs 6: 327–329

    Article  CAS  PubMed  Google Scholar 

  • Falkson G, Vorobiof DA, Lerner HJ (1983) A phase II study of m-AMSA in patients with malignant mesothelioma. Cancer Chemother Pharmacol 11: 94–97

    CAS  PubMed  Google Scholar 

  • Falkson G, Vorobiof DA, Simson IW et al. (1987) Phase II trial of acivicin in malignant mesothelioma. Cancer Treat Rep 71: 545–546

    CAS  PubMed  Google Scholar 

  • Falkson G, Hunt M, Borden EC et al. (1992) An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 10: 337–343

    Article  CAS  PubMed  Google Scholar 

  • Fizazi K, Caliandro R, Soulie P et al. (2000) Combination raltitrexed (Tomudex struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemoimmunotherapy in mesothelioma. Eur J Cancer 36: 1514–1521

    Article  CAS  PubMed  Google Scholar 

  • Fong TA, Shawver LK, Sun L et al. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99–106

    CAS  PubMed  Google Scholar 

  • Goey SH, Eggermont AM, Punt CJ et al. (1995) Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I–II study. Br J Cancer 72: 1283–1288

    CAS  PubMed  Google Scholar 

  • Gralla RJ, Hollen PJ, Liepa AM et al. (2003) Improving quality of life in patients with malignant pleural mesothelioma: Results of the randomised Pemetrexed and Cisplatin vs Cisplatin trial using the LCSS-Meso-Instrument. Proc ASCO 22: 621 (Abstr. 2496)

    Google Scholar 

  • Gridelli C, Pepe R, Airoma G et al. (1992) Mitomycin C and vindesine: an ineffective combination chemotherapy in the treatment of malignant pleural mesothelioma. Tumori 78: 380–238

    CAS  PubMed  Google Scholar 

  • Halme M, Knuuttila A, Vehmas T et al. (1999) High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. Br J Cancer 80: 1781–1785

    Article  CAS  PubMed  Google Scholar 

  • Harvey VJ, Slevin ML, Ponder BA et al. (1984) Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 54: 961–964

    CAS  PubMed  Google Scholar 

  • Henss H, Fiebig HH, Schildge J et al. (1988) Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura. Onkologie 11: 118–120

    CAS  PubMed  Google Scholar 

  • Hughes A, Calvert P, Azzabi A et al. (2002) Phase I clinical and pharmakokinetic study of Pemetrexed and Carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20: 3533–3544

    Article  CAS  PubMed  Google Scholar 

  • Icli F, Karaoguz H, Hasturk S et al. (1996) Two dose levels of ifosfamide in malignant mesothelioma. Lung Cancer 15: 207–213

    CAS  PubMed  Google Scholar 

  • Juturi JV, Adelstein DJ, Rice TW et al. (2001) Intracavitary paclitaxel in the multimodality management of malignant pleural mesothelioma. Proc ASCO 20: 366a (Abstr. 1460)

    Google Scholar 

  • Kaukel E, Koschel G, Gatzemeyer U et al. (1990) A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 66: 651–654

    CAS  PubMed  Google Scholar 

  • Kelsen D, Gralla R, Cheng E et al. (1983) Vindesine in the treatment of malignant mesothelioma: a phase II study. Cancer Treat Rep 67: 821–822

    CAS  PubMed  Google Scholar 

  • Kindler HL, Belani CP, Herndon JE 2nd et al. (1999) Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 86: 1985–1991

    Article  CAS  PubMed  Google Scholar 

  • Kindler HL, Herndon JE, Vogelzang NJ et al. (2000) CPT-11 in Malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 9733). Proc ASCO 19: 505a (Abstr.1978)

    Google Scholar 

  • Kindler HL Vogelzang NJ, Chien K et al. (2001a) SU5416 in Malignant Mesothelioma: a University of Chicago phase II consortium study. Proc ASCO 20: 341 (Abstr. 1359)

    Google Scholar 

  • Kindler HL, Millard F, Herndon JE 2nd et al. (2001b) Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 31: 311–317

    Article  CAS  PubMed  Google Scholar 

  • Knuuttila A, Ollikainen T, Halme M et al. (2000) Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma — a feasibility study. Anticancer Drugs 11: 257–261

    Article  CAS  PubMed  Google Scholar 

  • Krarup-Hansen A (1996) Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma. Lung Cancer 16: 101–102

    Article  CAS  PubMed  Google Scholar 

  • Lerner HJ, Schoenfeld DA, Martin A et al. (1983) Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52: 1981–1985

    CAS  PubMed  Google Scholar 

  • Linden CJ, Mercke C, Albrechtsson U et al. (1996). Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a non-randomized phase II study. Eur Respir J 9: 2565–2572

    CAS  PubMed  Google Scholar 

  • Magri MD, Veronesi A, Foladore S et al. (1991) Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE) — Mesothelioma Committee. Tumori 77: 49–51

    CAS  PubMed  Google Scholar 

  • Magri MD, Foladore S, Veronesi A et al. (1992) Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study. Ann Oncol 3: 237–238

    CAS  PubMed  Google Scholar 

  • Maksymiuk AW, Marschke RF Jr, Tazelaar HD et al. (1998) Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 21: 610–613

    Article  CAS  PubMed  Google Scholar 

  • Manegold C, Symanowski I, Gatzemeier U et al. (2003). Secondary (post-study) chemotherapy in the phase III study of Pemetrexed and Cisplatin in malignant pleural mesothelioma is associated with longer survival. Proc ASCO 22: 667 (Abstr. 2684)

    Google Scholar 

  • Martensson G, Sorenson S (1989) A phase II study of vincristine in malignant mesothelioma — a negative report. Cancer Chemother Pharmacol 24: 133–134

    CAS  PubMed  Google Scholar 

  • Mattson K, Giaccone G, Kirkpatrick A et al. (1992) Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10: 824–828

    CAS  PubMed  Google Scholar 

  • Mbidde EK, Harland SJ, Calvert AH et al. (1986) Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol 18: 284–285

    Article  CAS  PubMed  Google Scholar 

  • Mendel DB, Laird AD, Smolich BD et al. (2000) Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 15: 29–41

    CAS  PubMed  Google Scholar 

  • Metintas M, Ozdemir N, Ucgun I et al. (1999) Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 116: 391–398

    Article  CAS  PubMed  Google Scholar 

  • Middleton GW, Smith IE, O’Brien ME et al. (1998) Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9: 269–273

    Article  CAS  PubMed  Google Scholar 

  • Mintzer DM, Kelsen D, Frimmer D et al. (1985) Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 69: 711–712

    CAS  PubMed  Google Scholar 

  • Nakano T, Chahinian AP, Shinjo M et al. (1999) Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 85: 2375–2384

    Article  CAS  PubMed  Google Scholar 

  • Novak A, Byrne M, Williamson R (2002) Multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87: 491–496

    Google Scholar 

  • Oh Y, Perez-Soler R, Fossella FV et al. (2000) Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 18: 243–245

    Article  CAS  PubMed  Google Scholar 

  • Ohta Y, Shridhar V, Bright RK et al. (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81: 54–61

    Article  CAS  PubMed  Google Scholar 

  • Ollikainen T, Knuuttila A, Suhonen S et al. (2000) In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents. Anticancer Drugs

    Google Scholar 

  • O’Reilly EM, Ilson DH, Saltz LB et al. (1999) A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest 17: 195–200

    CAS  PubMed  Google Scholar 

  • Parra HS, Tixi L, Latteri F et al. (2001) Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 92: 650–656

    Article  CAS  PubMed  Google Scholar 

  • Pass HW, Temeck BK, Kranda K et al. (1995) A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 2: 214–220

    CAS  PubMed  Google Scholar 

  • Pass HI, Temeck BK, Kranda K et al. (1998) Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 115: 310–318

    CAS  PubMed  Google Scholar 

  • Pennucci MC, Ardizzoni A, Pronzato P et al. (1997) Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer 79: 1897–1902

    Article  CAS  PubMed  Google Scholar 

  • Pinto C, Marino A, Guaraldi M et al. (2001) Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 24: 143–147

    Article  CAS  PubMed  Google Scholar 

  • Planting AS, van der Burg ME, Goey SH et al. (1995) Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 6: 613–615

    CAS  PubMed  Google Scholar 

  • Purohit A, Moreau L, Dietemann A et al. (1998) Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma. Lung Cancer 22: 119–125

    Article  CAS  PubMed  Google Scholar 

  • Raghavan D, Gianoutsos P, Bishop J et al. (1990) Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8: 151–154

    CAS  PubMed  Google Scholar 

  • Rusch VW, Venkatraman E (1996) The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111: 815–825

    CAS  PubMed  Google Scholar 

  • Ryan CW, Herndon J, Vogelzang NJ (1998) A review of chemotherapy trials for malignant mesothelioma. Chest 113: 66–73

    Google Scholar 

  • Sahmoud T, Postmus PE, van Pottelsberghe C et al. (1997) Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 33: 2211–2215

    Article  CAS  PubMed  Google Scholar 

  • Samson MK, Wasser LP, Borden EC et al. (1987) Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 5: 86–91

    CAS  PubMed  Google Scholar 

  • Samuels BL, Herndon JE 2nd, Harmon DC et al. (1998) Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 82: 1578–1584

    Article  CAS  PubMed  Google Scholar 

  • Scagliotti GV, Shin DM, Kindler HL et al. (2003) Phase II study of Pemetrexed with or without folic acid and vitamin B12 as frontline therapy in malignant pleural mesothelioma. J Clin Oncol 21: 1556–1561

    Article  CAS  PubMed  Google Scholar 

  • Schütte W, Blankenburg T, Lauerwald K et al. (2003) A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 4(5): 294–297

    PubMed  Google Scholar 

  • Shih C, Gosset L, Gates S et al. (1996) LH 231514 and its poly-glutamates exhibit potent inhibition against both human dihydrofolate reductase and thymidylate synthase: multiple folate enzyme inhibition. Ann Oncol 7(Suppl 1): 85

    Google Scholar 

  • Shin DM, Fossella FV, Umsawasdi T et al. (1995) Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76: 2230–2236

    CAS  PubMed  Google Scholar 

  • Shin DM, Walsh GL, Smythe WR et al. (2000) Pathologic response with liposomal entrapped cisplatin (L-NDDP) administered in patients with malignant pleural mesothelioma: Phase II clinical study. Lung Cancer 29(Suppl 1): 19 (Abstr. 57)

    Google Scholar 

  • Sklarin NT, Chahinian AP, Feuer EJ et al. (1988) Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 48: 64–67

    CAS  PubMed  Google Scholar 

  • Solheim OP, Saeter G, Finnanger AM et al. (1992) High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65: 956–960

    CAS  PubMed  Google Scholar 

  • Sorensen PG, Bach F, Bork E et al. (1985) Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69: 1431–1432

    CAS  PubMed  Google Scholar 

  • Soulie P, Ruffie P, Trandafir L et al. (1996) Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I–II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 14: 878–885

    CAS  PubMed  Google Scholar 

  • Sridhar KS, Hussein AM, Feun LG et al. (1989) Activity of pirarubicin (4′-0-tetrahydropyranyladriamycin) in malignant mesothelioma. Cancer 63: 1084–1091

    CAS  PubMed  Google Scholar 

  • Steele JP, Rudd RM (2000) Malignant mesothelioma: predictors of prognosis and clinical trials. Thorax 55: 725–726

    Article  CAS  PubMed  Google Scholar 

  • Steele JP, Shamash J, Evans MT et al. (2000a) Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 18: 3912–3917

    CAS  PubMed  Google Scholar 

  • Steele JP, Shamsh J, Evans MT et al. (2000b) Phase II trial of vinorelbine and oxaliplatin in patients with malignant pleural mesothelioma. Lung Cancer 29(Suppl 1): 18 (Abstr. 54)

    Google Scholar 

  • Steele JP, O’Doherty CA, Shamash J et al. (2001) Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 12: 497–499

    Article  CAS  PubMed  Google Scholar 

  • Sterman DH, Kaiser LR, Albelda SM (1999) Advances in the treatment of malignant pleural mesothelioma. Chest 116: 504–520

    Article  CAS  PubMed  Google Scholar 

  • Tammilehto L, Maasilta P, Mantyla M et al. (1994) Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann Oncol 5: 949–950

    CAS  PubMed  Google Scholar 

  • Tansan S, Emri S, Selcuk T et al. (1994) Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 51: 348–351

    CAS  PubMed  Google Scholar 

  • Taub RN, Antman KH (1997) Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc Surg 9: 361–366

    CAS  PubMed  Google Scholar 

  • Taub RN, Keohan ML, Vogelzang NJ et al. (1999) Phase II Trial of Onconase® in Patients with Advanced Malignant Mesothelioma: Analysis of survival. Proc ASCO 18: 524a (Abstr. 2021)

    Google Scholar 

  • Thoedtmann R, Depenbrock H, Dumez H et al. (1999) Clinical and pharmakokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17: 3009–3016

    Google Scholar 

  • Trandafir L, Ruffie P, Borel C et al. (1997) Higher doses of alphainterferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur J Cancer 33: 1900–1902

    Article  CAS  PubMed  Google Scholar 

  • Tsavaris N, Mylonakis N, Karvounis N et al. (1994) Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 11: 299–303

    Article  CAS  PubMed  Google Scholar 

  • Upham JW, Musk AW, van Hazel G et al. (1993) Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 23: 683–687

    CAS  PubMed  Google Scholar 

  • van Breukelen FJ, Mattson K, Giaccone G et al. (1991) Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 27: 1627–1629

    PubMed  Google Scholar 

  • van Haarst JW, Burgers JA, Manegold C et al. (2000) Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM). Lung Cancer 29(Suppl 1): 18 (Abstr. 56)

    Google Scholar 

  • van Meerbeeck J, Debruyne C, van Zandwijk N et al. (1996) Paclitaxel for malignant pleural mesothelioma: a phase II-study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 74: 961–963

    PubMed  Google Scholar 

  • van Meerbeeck JP, Baas P, Debruyne C et al. (1999) A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 85: 2577–2582

    PubMed  Google Scholar 

  • Verschraegen C, Le D, Kudelka A et al. (2001) Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Proc ASCO 20: 906 (Abstr. 2110)

    Google Scholar 

  • Vogelzang NJ, Goutsou M, Corson JM et al. (1990) Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 27: 239–242

    Article  CAS  PubMed  Google Scholar 

  • Vogelzang NJ, Weissman LB, Herndon JE 2nd et al. (1994) Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol 12: 1436–1442

    CAS  PubMed  Google Scholar 

  • Vogelzang NJ, Herndon JE 2nd, Cirrincione C et al. (1997) Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 79: 2237–2242

    Article  CAS  Google Scholar 

  • Vogelzang NJ, Herndon JE 2nd, Miller A et al. (1999) High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 10: 597–600

    Article  CAS  PubMed  Google Scholar 

  • Vogelzang N, Taub R, Shin P et al. (2002) Phase III randomised trial of Onconase vs doxorubicin in patients with unresectable malignant mesothelioma: analysis of survival. Proc ASCO 19: 577a (Abstr. 2274)

    Google Scholar 

  • Vogelzang NJ, Rusthoven JJ, Symanowski J et al. (2004) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636–2644

    Google Scholar 

  • Von Hoff DD, Huong AM (1988) Effect of recombinant interferon-beta ser on primary human tumor colony-forming units. J Interferon Res 8: 813–820

    Google Scholar 

  • Von Hoff DD, Metch B, Lucas JG et al. (1990) Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res 10: 531–534

    Google Scholar 

  • Vorobiof DA, Chasen MR, Abratt R et al. (2000) Taxotere in malignant pleural mesothelioma. A Phase II clinical trial. Lung Cancer 29(Suppl 1): 19 (Abstr. 58)

    Google Scholar 

  • Webster I, Cochrane JW, Burkhardt KR (1982) Immunotherapy with BCG vaccine in 30 cases of mesothelioma. S Afr Med J 61: 277–278

    CAS  PubMed  Google Scholar 

  • White SC, Anderson H, Jayson GC et al. (2000) Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma. Ann Oncol 11: 201–206

    Article  CAS  PubMed  Google Scholar 

  • Zidar BL, Benjamin RS, Frank J et al. (1983) Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study. Am J Clin Oncol 6: 71–74

    CAS  PubMed  Google Scholar 

  • Zidar BL, Green S, Pierce HI et al. (1988) A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 6: 223–226

    Article  CAS  PubMed  Google Scholar 

  • Zidar BL, Metch B, Balcerzak SP et al. (1992) A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 70: 2547–2551

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin I Klinische Abteilung für Onkologie, Universitätsklinikum Wien, Währinger Str. 18-20, 1090, Wien, Austria

    S. Tomek

  2. Chirurgische Klinik, Klinikum Mannheim der Ruprecht-Karls-Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim

    Prof. Dr. med. Ch. Manegold

Authors
  1. S. Tomek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Ch. Manegold
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Tomek, S., Manegold, C. (2005). Chemotherapie des malignen Pleuramesothelioms. In: Pleuramesotheliom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27329-8_9

Download citation

  • DOI: https://doi.org/10.1007/3-540-27329-8_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-23014-4

  • Online ISBN: 978-3-540-27329-5

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation